HomeCompareKARBF vs BTI

KARBF vs BTI: Dividend Comparison 2026

KARBF yields 38.10% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KARBF wins by $171.2K in total portfolio value
10 years
KARBF
KARBF
● Live price
38.10%
Share price
$5.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$208.9K
Annual income
$33,891.10
Full KARBF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — KARBF vs BTI

📍 KARBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKARBFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KARBF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KARBF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KARBF
Annual income on $10K today (after 15% tax)
$3,238.10/yr
After 10yr DRIP, annual income (after tax)
$28,807.43/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, KARBF beats the other by $26,438.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KARBF + BTI for your $10,000?

KARBF: 50%BTI: 50%
100% BTI50/50100% KARBF
Portfolio after 10yr
$123.3K
Annual income
$18,338.87/yr
Blended yield
14.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

KARBF
No analyst data
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KARBF buys
0
BTI buys
0
No recent congressional trades found for KARBF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKARBFBTI
Forward yield38.10%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$208.9K$37.7K
Annual income after 10y$33,891.10$2,786.64
Total dividends collected$154.9K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: KARBF vs BTI ($10,000, DRIP)

YearKARBF PortfolioKARBF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$14,510$3,809.52$11,299$598.92+$3.2KKARBF
2$20,691$5,165.83$12,794$703.91+$7.9KKARBF
3$29,024$6,884.70$14,518$829.07+$14.5KKARBF
4$40,081$9,025.64$16,513$978.64+$23.6KKARBF
5$54,536$11,648.73$18,827$1,157.84+$35.7KKARBF
6$73,166$14,812.69$21,518$1,373.12+$51.6KKARBF
7$96,860$18,572.81$24,657$1,632.46+$72.2KKARBF
8$126,620$22,978.99$28,329$1,945.74+$98.3KKARBF
9$163,557$28,073.84$32,637$2,325.33+$130.9KKARBF
10$208,897$33,891.10$37,708$2,786.64+$171.2KKARBF

KARBF vs BTI: Complete Analysis 2026

KARBFStock

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands. It sells its products in approximately 90 countries with Europe and the Nordic region markets through direct sales organizations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.

Full KARBF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this KARBF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KARBF vs SCHDKARBF vs JEPIKARBF vs OKARBF vs KOKARBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.